胆管癌组织中赖氨酰氧化酶样蛋白-2的表达及其与EMT的关系  

LOXL2 and its relation with epithelial-mesenchymal transition cholangiocarcinoma

作　　者：高应鸿[1] 李天宇[1] 高占峰[1] 蒋卫伟[1] 王曙光[1] 

机构地区：[1]第三军医大学西南医院全军肝胆外利研究所,重庆400038

出　　处：《中华普通外科杂志》2008年第10期784-787,共4页Chinese Journal of General Surgery

摘　　要：目的研究赖氨酰氧化酶样蛋白-2（lysyl oxidase like-2 protein，LOXL2）及上皮-间叶样表型转化（epithelial—mesenchymal transition，EMT）标志物在人胆管癌组织中的表达及其与胆管癌恶性生物学行为的关系。方法采用免疫组织化学方法检测48例人胆管癌组织中LOXL2、E—eadherin、Vimentin蛋白的表达，同时结合患者的临床病理资料进行分析。结果48例胆管癌组织中LOXL2、Vimentin蛋白的阳性表达率分别是71％（34／48）、46％（22／48），E—eadherin蛋白的表达缺失率为52％（25／48）。胆管癌组织中LOXL2和E—cadherin表达缺失（r=0．394，P〈0．05）、Vimentin的表达（r=0．406，P〈0．05）具有正相关性，同时LOXL2蛋白的阳性表达与肿瘤发生转移差异具有统计学意义（X^2=6．05，P〈0．05），而与性别、年龄、肿瘤部位、肿瘤类型、肿瘤分化程度等无关。另外，Vimentin蛋白阳性表达（X^2=6．467，P〈0．05）、E—cadherin表达缺失（X^2=4．057，P〈0．05）与胆管癌的转移差异有统计学意义。结论LOXL2蛋白在胆管癌组织中呈高表达，并可能通过诱导胆管癌组织EMT促进胆管癌的浸润和转移。Objective To in-vestigate the expression of LOXL2 protein （lysyl oxidase like-2 protein） and epithelial-mesenchymal transition （EMT） related markers in cholangiocarcinoma tissues and its relation with the malignant features. Methods The expression of LOXL2 ,E-cadherin and Vimentin protein in 48 cases of cholangiocarcinoma tissues was detected by immunohistochemistry and compared with the clinicopathological data of cholangiocarcinoma. Results The positive expression rate in cholangiocarcinoma was 71% （34/48） for LOXL2 and 46% （22/48） for Vimentin, the absent expression rate was 52% （25/48） for E-cadherin. The positive expression rate of LOXL2 was significantly associated with the absent expression of epithelium markers E-cadherin （ r = 0. 394, P 〈 0. 05 ） and the positive expression of fibroblast markers Vimentin （r = 0. 406, P 〈 0. 05 ）. There was no correlation between the expression of LOXL2 and patients gender, age, and cancer differentiation, but a significant correlation with tumor metastasis was found （P 〈 0. 05 ）. Conclusions LOXL2 protein overexpression in cholangiocarcinoma may accelerate invasion of cholangiocareinoma through induced EMT.

关 键 词：胆管肿瘤 免疫组织化学 LOXL2蛋白 表型转化 

分 类 号：R686[医药卫生—骨科学]